BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 13, 2008
View Archived Issues
Despite Tough Market, Aldagen's IPO Seeks $81M for Cell Therapy
With its lead cell therapy program in a pivotal study, Aldagen Inc. has decided to brave the public markets. (BioWorld Today)
Read More
Cell Genesys Snagging $30M to Push Late-Stage GVAX
Read More
Long-Term UK Bio Investor Prelude Trust Calling it Quits
Read More
Novelos Antitumor Drug Hits Efficacy Mark Early in Trial
Read More
Other News To Note
Read More
Earnings Roundup
Read More
U.S. Patent Disclosures
Read More
Clinic Roundup
Read More